Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BIIB

Biogen Inc

Sep 15 • 03:42PM ET

143.95

-0.91 -0.63 %

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO QQQ VO SPY IVV VTV COWZ RSP XLV

Scroll to Statements

Index	NDX, S&P 500	P/E	13.77	EPS (ttm)	10.45	Insider Own	0.19%	Shs Outstand	146.60M	Perf Week	1.84%
Market Cap	21.11B	Forward P/E	9.10	EPS next Y	15.81	Insider Trans	-1.87%	Shs Float	146.34M	Perf Month	6.68%
Enterprise Value	24.94B	PEG	-	EPS next Q	3.84	Inst Own	89.79%	Short Float	3.23%	Perf Quarter	10.18%
Income	1.53B	P/S	2.20	EPS this Y	-3.83%	Inst Trans	-0.08%	Short Ratio	3.30	Perf Half Y	3.24%
Sales	9.61B	P/B	1.20	EPS next Y	-0.16%	ROA	5.55%	Short Interest	4.72M	Perf YTD	-5.86%
Book/sh	120.29	P/C	7.65	EPS next 5Y	-0.27%	ROE	9.13%	52W High	204.18 -29.50%	Perf Year	-27.69%
Cash/sh	18.82	P/FCF	10.67	EPS past 3/5Y	2.46% -18.66%	ROIC	6.32%	52W Low	110.04 30.82%	Perf 3Y	-28.26%
Dividend Est.	-	EV/EBITDA	8.03	Sales past 3/5Y	-3.78% -6.13%	Gross Margin	66.28%	Volatility	3.52% 2.94%	Perf 5Y	-47.87%
Dividend TTM	-	EV/Sales	2.60	EPS Y/Y TTM	31.44%	Oper. Margin	24.15%	ATR (14)	4.46	Perf 10Y	-48.63%
Dividend Ex-Date	-	Quick Ratio	1.79	Sales Y/Y TTM	3.48%	Profit Margin	15.93%	RSI (14)	59.16	Recom	2.18
Dividend Gr. 3/5Y	- -	Current Ratio	2.50	EPS Q/Q	8.18%	SMA20	3.06%	Beta	0.12	Target Price	169.23
Payout	0.00%	Debt/Eq	0.37	Sales Q/Q	8.86%	SMA50	7.25%	Rel Volume	0.69	Prev Close	144.86
Employees	7605	LT Debt/Eq	0.37	Earnings	Jul 31 BMO	SMA200	5.58%	Avg Volume	1.43M	Price	143.95
IPO	Sep 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	40.31% 13.63%	Trades		Volume	937,463	Change	-0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-25	Resumed	Truist	Hold	$142
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360

Show Previous Ratings

Today 09:03AM	H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects (Insider Monkey)
Sep-12-25 01:56PM	Is Biogen Stock Underperforming the Nasdaq? (Barchart)
Sep-11-25 07:00AM	GE HealthCare inks Icometrix buyout to acquire brain MRI software (MedTech Dive)
Sep-09-25 04:00AM	Can new Alzheimers tests help clear the way for the next generation of therapies? (Pharma Voice)
Sep-04-25 02:36PM	Biogen (BIIB) Stock Trades Down, Here Is Why (StockStory)
09:17AM	Loading…
09:17AM	Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth? (Zacks)
Sep-03-25 10:47AM	IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride (Zacks)
Sep-02-25 09:05PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research) +5.60%
07:30PM	Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status (GlobeNewswire)
03:35PM	Biogen (BIIB) Stock Is Up, What You Need To Know (StockStory)
10:23AM	Stock Market Today: Nasdaq, S&P 500 down over 1% after holiday weekend (TheStreet)
10:01AM	Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales (Zacks)
09:51AM	Stock Market Today: Dow Dives 500 Points On Trump Tariff News; Nvidia, Palantir Sell Off (Live Coverage) (Investor's Business Daily)
09:48AM	These Stocks Are Moving the Most Today: Nvidia, PepsiCo, NIO, Constellation Brands, Biogen, and More (Barrons.com)
08:20AM	Amgen to invest $600M in new US center; Sanofi drug for ITP approved (BioPharma Dive)
07:00AM	Loading…
07:00AM	Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome (GlobeNewswire)
03:30AM	Biogen Inc. (BIIB)'s Alzheimer's Drug Leqembi Wins EU Nod, Now Approved in 48 Countries (Insider Monkey)
02:30AM	Startup Corsera Health aims to bring preventive heart medicine to the masses (BioPharma Dive)
Sep-01-25 10:31AM	Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi (Zacks)
07:15AM	FDA approves Eisai and Biogen's Leqembi Iqlik BLA for early Alzheimer's (Pharmaceutical Business Review)
Aug-29-25 05:06PM	FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment (Investor's Business Daily) +5.60%
05:00PM	FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease (PR Newswire)
Aug-25-25 07:00AM	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress (GlobeNewswire)
03:00AM	Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI (lecanemab) (GlobeNewswire)
Aug-21-25 05:49PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
05:05AM	Biogen Stock: Analyst Estimates & Ratings (Barchart)
Aug-19-25 07:25PM	Analyst Report: Biogen Inc. (Morningstar Research)
Aug-13-25 05:50PM	Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know (StockStory)
11:48PM	Loading…
Aug-12-25 11:48PM	BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance (StockStory)
11:46PM	5 Revealing Analyst Questions From Biogen's Q2 Earnings Call (StockStory)
10:30PM	[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
08:48AM	New .med Domain Names Surpass 40,000 Pre-Orders in July (PR Newswire)
08:18AM	DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 (Zacks)
06:38AM	First patient dosed in Phase III trial of zorevunersen for Dravet syndrome (Clinical Trials Arena)
Aug-11-25 07:00AM	Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome (GlobeNewswire)
05:48AM	Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 \| Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035 (GlobeNewswire)
02:00AM	Gilead Stock Is Closing In on an All-Time High. The Case for More Upside. (Barrons.com)
02:00AM	Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside. (Barrons.com)
Aug-06-25 05:45PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
Aug-04-25 04:05PM	Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer (Business Wire)
01:32PM	Biogen Inc. (BIIB): A Bull Case Theory (Insider Monkey)
Aug-01-25 07:10AM	Regeneron cancer bispecific rejected again; Allogene discloses trial death (BioPharma Dive)
07:09AM	Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics (Pharmaceutical Technology)
04:00AM	Merck & Co. assembles an Alzheimers comeback with a next-gen precision focus (Pharma Voice)
01:44AM	Analyst Report: Biogen Inc. (Morningstar Research)
Jul-31-25 11:49AM	Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate (Benzinga)
10:48AM	Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up (Zacks)
09:30AM	Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:10AM	Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook (Zacks)
07:27AM	Biogen Q2 Results Top Estimates; Boosts FY25 Outlook (RTT News)
07:24AM	Biogen (NASDAQ:BIIB) Reports Bullish Q2 (StockStory)
07:20AM	Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
06:49AM	Biogen lifts full-year outlook amid Alzheimers drug strength, sending shares up (Investing.com)
06:23AM	Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025 (PR Newswire)
06:17AM	Biogen raises annual profit forecast on strong demand for rare disease drugs (Reuters)
05:43AM	Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA (GlobeNewswire)
12:16AM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Jul-30-25 04:05PM	Sage Therapeutics Announces Second Quarter 2025 Financial Results (Business Wire)
11:00AM	Two-Year Real-World Study of LEQEMBI in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 (GlobeNewswire)
09:15AM	Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
09:00AM	New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease (PR Newswire)
08:07AM	Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC (PR Newswire)
05:41AM	Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL (Clinical Trials Arena)
Jul-29-25 11:06PM	Biogen Earnings: What To Look For From BIIB (StockStory)
01:39AM	Biogen (BIIB) to Invest $2 Billion in U.S. Expansion Amid Onshoring Push (Insider Monkey)
Jul-28-25 04:13PM	Biotech stocks dip as Trump administration mulls patent fee overhaul (Investing.com)
10:24AM	Biogen Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
10:00AM	BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-25-25 07:20AM	ZURZUVAE (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression (GlobeNewswire)
Jul-24-25 10:00AM	Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-23-25 10:41AM	Amyotrophic Lateral Sclerosis (ALS) Market Forecast Report 2025-2034 \| Advancements in Therapeutics and Approved Medications Such as Riluzole, Edaravone, and Nuedexta Drive Growth (GlobeNewswire)
Jul-22-25 09:31AM	How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? (Zacks)
05:13AM	Biogen to invest further $2bn in North Carolinas Research Triangle Park (Pharmaceutical Technology)
Jul-21-25 07:30PM	Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025 (GlobeNewswire)
06:31PM	Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome (Insider Monkey)
03:31PM	Biogen (BIIB) Stock Trades Down, Here Is Why (StockStory)
01:14PM	Biogen beefs up North Carolina manufacturing ahead of potential Trump tariff (Asheville Citizen-Times)
09:40AM	Target downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
07:41AM	Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm (Reuters)
07:30AM	Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary (GlobeNewswire)
Jul-18-25 08:12PM	Analyst Report: Biogen Inc. (Morningstar Research)
08:21AM	Here's What to Expect From Biogen's Next Earnings Report (Barchart)
Jul-17-25 07:00AM	Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States (Business Wire)
07:00AM	Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States (Business Wire)
Jul-16-25 03:53AM	The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association (PR Newswire)
Jul-15-25 04:00AM	Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors (GlobeNewswire)
Jul-14-25 04:01AM	Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035 \| Increase in Clinical Trials and Investments will Accelerate the Development of Innovative Treatments (GlobeNewswire)
Jul-11-25 07:34PM	Analyst Report: Biogen Inc. (Morningstar Research)
Jul-10-25 11:14AM	RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT (Insider Monkey)
07:00AM	Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (GlobeNewswire)
Jul-08-25 09:59AM	DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review (Zacks)
Jul-02-25 07:11PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Jul-01-25 10:50AM	Biogen Begins Phase III Felzartamab Study for Third Kidney Disease (Zacks)
12:03AM	3 Reasons BIIB is Risky and 1 Stock to Buy Instead (StockStory)
Jun-30-25 08:42AM	AbbVie to buy Capstan for up to $2.1 billion in immunology push (Reuters)
08:18AM	RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimers market (Investing.com)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Singhal Priya	Head of Development	Aug 29 '25	Option Exercise	0.00	1,669	0	7,096	Sep 02 05:56 PM
Singhal Priya	Head of Development	Sep 02 '25	Sale	133.55	517	69,045	5,772	Sep 02 05:56 PM
Singhal Priya	Officer	Sep 02 '25	Proposed Sale	133.55	517	69,045		Sep 02 12:54 PM
Izzar Rachid	Head of Global Product Strat.	Jul 08 '25	Sale	135.00	2,223	300,105	6,330	Jul 16 05:55 PM
Izzar Rachid	Officer	Jul 08 '25	Proposed Sale	135.00	2,223	300,105		Jul 08 03:26 PM
Singhal Priya	Head of Development	May 19 '25	Sale	126.25	3,806	480,508	5,427	May 20 04:05 PM
Singhal Priya	Officer	May 19 '25	Proposed Sale	126.25	3,806	480,508		May 19 11:24 AM
Keeney Adam	Head of Corporate Development	May 01 '25	Option Exercise	0.00	938	0	2,838	May 05 04:19 PM
DORSA CAROLINE	Director	May 02 '25	Buy	122.72	1,235	151,559	27,842	May 05 04:17 PM
SHERWIN STEPHEN A	Director	Mar 07 '25	Sale	150.02	8,760	1,314,142	11,318	Mar 10 04:09 PM
STEPHEN A SHERWIN	Director	Mar 07 '25	Proposed Sale	147.37	8,760	1,290,961		Mar 07 04:18 PM
Singhal Priya	Head of Development	Feb 10 '25	Option Exercise	0.00	1,212	0	9,423	Feb 12 05:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10 '25	Option Exercise	0.00	2,272	0	14,725	Feb 12 05:47 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10 '25	Option Exercise	0.00	3,257	0	25,712	Feb 12 05:46 PM
Kramer Robin	Chief Accounting Officer	Feb 10 '25	Option Exercise	0.00	834	0	8,257	Feb 12 05:44 PM
Gregory Ginger	EVP, Human Resources	Feb 10 '25	Option Exercise	0.00	2,159	0	18,232	Feb 12 05:43 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 10 '25	Option Exercise	0.00	2,575	0	37,072	Feb 12 05:42 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10 '25	Option Exercise	0.00	1,515	0	8,998	Feb 12 05:40 PM
Izzar Rachid	Head of Global Product Strat.	Feb 07 '25	Option Exercise	0.00	3,844	0	7,860	Feb 11 09:52 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 07 '25	Option Exercise	0.00	4,551	0	23,171	Feb 10 06:59 PM
Viehbacher Christopher	President and CEO	Feb 07 '25	Option Exercise	0.00	9,008	0	16,008	Feb 10 06:55 PM
Grogan Jane	Head of Research	Feb 07 '25	Option Exercise	0.00	1,385	0	1,876	Feb 10 06:52 PM
Keeney Adam	Head of Corporate Development	Feb 07 '25	Option Exercise	0.00	1,801	0	2,463	Feb 10 06:51 PM
Kramer Robin	Chief Accounting Officer	Feb 07 '25	Option Exercise	0.00	1,491	0	7,667	Feb 10 06:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 07 '25	Option Exercise	0.00	4,042	0	13,056	Feb 10 06:47 PM
Singhal Priya	Head of Development	Feb 07 '25	Option Exercise	0.00	2,216	0	8,892	Feb 10 06:45 PM
Gregory Ginger	EVP, Human Resources	Feb 07 '25	Option Exercise	0.00	3,436	0	16,633	Feb 10 06:44 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 07 '25	Option Exercise	0.00	4,130	0	35,088	Feb 10 06:42 PM
Singhal Priya	Head of Development	Jan 31 '25	Option Exercise	0.00	1,828	0	7,254	Feb 03 06:02 PM
Singhal Priya	Head of Development	Dec 06 '24	Option Exercise	0.00	426	0	5,742	Dec 09 04:57 PM
Singhal Priya	Head of Development	Dec 09 '24	Sale	157.21	110	17,293	5,426	Dec 09 04:57 PM
Kramer Robin	Chief Accounting Officer	Dec 06 '24	Option Exercise	0.00	351	0	6,578	Dec 09 04:56 PM
Singhal Priya	Officer	Dec 09 '24	Proposed Sale	157.21	110	17,293		Dec 09 10:33 AM
Grogan Jane	Head of Research	Nov 01 '24	Option Exercise	0.00	695	0	695	Nov 04 04:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIIB

Biogen Inc

Upgrade your FINVIZ experience